Evidence map›Paper›PMID 15645121›Full record

ArticleInternational journal of oncology2005

Frequent trefoil factor 3 (TFF3) overexpression and promoter hypomethylation in mouse and human hepatocellular carcinomas.

Haruhiko Okada, Makoto T Kimura, Dongfeng Tan, Kyoko Fujiwara, Jun Igarashi, Masatoshi Makuuchi, Ai-Min Hui, Masahiko Tsurumaru, Hiroki Nagase

Abstract read
In one paragraph

Article in International journal of oncology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 50 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. The long non-coding RNACell stress · 2017
    Article
  15. Article
  16. Clinical epigenetics · 2017
    Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Haruhiko OkadaDepartment of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
Makoto T Kimura
Dongfeng Tan
Kyoko Fujiwara
Jun Igarashi
Masatoshi Makuuchi
Ai-Min Hui
Masahiko Tsurumaru
Hiroki Nagase
Roswell Park Comprehensive Cancer Center · US

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MARK G FRATTINI · 1985 to 2026
$116.6M
Analysis and Identification of Skin Cancer in MiceR01ES012249 · NIEHS · ROSWELL PARK CANCER INSTITUTE CORP · PI NAGASE, HIROKI · 2004 to 2008
$2.0M
NCI NIH HHS CA16056NCI NIH HHS P30 CA016056NIEHS NIH HHS ES012249-01NIEHS NIH HHS R01 ES012249
6 · The paper itself

Abstract

Expression profiling analysis revealed ectopic high expression of mouse TFF3 in non-tumor liver tissues from the hepatocellular carcinoma (HCC) susceptible PWK/Rbrc strain. TFF3 is a member of the trefoil factor family peptides, which are small secreted proteins regulating mucosal regeneration and repair, and which are overexpressed during inflammatory processes and cancer progression. We, therefore, analyzed the TFF3 expression extensively in mouse and human HCCs. Expression of the mouse TFF3 gene was significantly increased in 6 out of 7 HCCs from a PWK spontaneous tumor model and in all 7 HCCs from an SV40T antigen-induced transgenic MT-D2C57BL/6 model. In humans, 8 of 20 HCCs (40%) had overexpression of TFF3 in both mRNA level and protein level. We then analyzed DNA methylation patterns of the TFF3 promoter region to evaluate expression regulation of promoter methylation. In mouse HCCs, we demonstrated that two CpGs, at positions -992 and +109, were hypomethylated in 13 of 14 mouse HCCs. In human HCCs, hypomethylation at CpG -260 was associated with TFF3 overexpression (p=0.04). These results indicate that TFF3 overexpression may be a critical process in mouse and human hepatocellular carcinogenesis, and the specific promoter CpG hypomethylation may be one of the regulation mechanisms of TFF3 overexpression in HCCs.

Indexed as

DNA MethylationGene Expression Regulation, NeoplasticPromoter Regions, GeneticAnimalsCarcinoma, HepatocellularComputational BiologyCpG IslandsCrosses, GeneticDisease ProgressionDNA PrimersHumansImmunohistochemistryMaleMiceMice, Inbred C3HMucinsDNA PrimersMucinsMuscle ProteinsPeptidesRNA, MessengerSulfitesTFF3 protein, humanTrefoil Factor-3

Identifiers

PMID15645121
PMCPMC2292801
OpenAlexW2116920679

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.